Vall d´Hebron Institute of Oncology´s Molecular Oncology Group
Deadline for submission of applications: 30/04/2018
Number of vacancies: 1
We are currently inviting applications for the appointment of a Pathologist to join our Molecular Oncology Group at the Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Our group has internationally recognized expertise in studying and testing hypothesis-based targeted therapy in oncology. Specifically, the successful candidate will be involved in VHIO´s molecular prescreening program to analyze tissue-based biomarkers by immunohistochemistry and fluorescent in situ hybridization.
He/she will also participate in multiple clinical trials for which our group acts as central or local laboratory as well as collaborate closely with our basic and translational researchers in projects aimed at gaining essential insights into basic cancer biology, mechanisms of action, and resistance to targeted therapies. If interested, he/she may also have the opportunity to join a PhD program of the Universitat Autónoma de Barcelona (UAB).
A highly driven research-oriented pathologist with the following minimum requirements and experience:
- Degree in Medicine
- Board-certification in Pathology
- Fluency in English
- Experience in immunopathology and working in similar positions will be favourably considered
Candidates should submit a cover letter describing their research interests, curriculum vitae, and names and contact information for 2-3 references via email to: email@example.com. Please specify ´Pathologist Position´ in the subject line.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), created by José Baselga in 2006, has established itself as a comprehensive cancer centre of proven excellence internationally. It is thanks to Josep´s directorship and VHIO´s optimal organisational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO´s pioneering model and programmes, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumour types.
VHIO´s translation toward precision oncology: http://www.vhio.net